Daiichi Sankyo Co Ltd (DSNKY)
28.15
+0.37
(+1.33%)
USD |
OTCM |
Dec 20, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 53.23B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 6.28% |
| Valuation | |
| PE Ratio | 35.38 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.773 |
| Price to Book Value | 4.685 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.1966 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0603 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 51.52% |
Profile
| Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer. |
| URL | https://www.daiichisankyo.com |
| Investor Relations URL | https://www.daiichisankyo.com/investors/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Feb. 06, 2025 (est.) |
| Last Earnings Release | Oct. 31, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 30, 2024 |
Ratings
Profile
| Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer. |
| URL | https://www.daiichisankyo.com |
| Investor Relations URL | https://www.daiichisankyo.com/investors/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Feb. 06, 2025 (est.) |
| Last Earnings Release | Oct. 31, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 30, 2024 |